LivaNova PLC (NASDAQ:LIVN) Director Sells $63,737.50 in Stock

LivaNova PLC (NASDAQ:LIVN) Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

LivaNova Stock Performance

Shares of NASDAQ:LIVN traded down $0.61 during midday trading on Friday, reaching $51.50. The company had a trading volume of 515,183 shares, compared to its average volume of 609,560. The stock has a market cap of $2.80 billion, a P/E ratio of 123.19 and a beta of 0.98. The company’s 50 day moving average price is $52.02 and its 200 day moving average price is $51.60. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 52-week low of $43.15 and a 52-week high of $64.47.

Analyst Ratings Changes

A number of research firms have issued reports on LIVN. Mizuho cut their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Needham & Company LLC reiterated a “buy” rating and set a $75.00 price target on shares of LivaNova in a report on Monday, November 25th. Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Robert W. Baird upped their target price on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Finally, The Goldman Sachs Group assumed coverage on shares of LivaNova in a research report on Friday, October 4th. They set a “buy” rating and a $65.00 price target on the stock. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, LivaNova has a consensus rating of “Buy” and an average target price of $69.17.

Institutional Investors Weigh In On LivaNova

Large investors have recently modified their holdings of the stock. Point72 Asset Management L.P. grew its holdings in LivaNova by 204.3% during the second quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company’s stock valued at $70,479,000 after purchasing an additional 863,157 shares during the period. First Light Asset Management LLC lifted its position in shares of LivaNova by 591.1% during the 2nd quarter. First Light Asset Management LLC now owns 710,390 shares of the company’s stock valued at $38,944,000 after buying an additional 607,598 shares during the last quarter. Great Lakes Advisors LLC bought a new position in shares of LivaNova during the 2nd quarter worth $16,614,000. Driehaus Capital Management LLC increased its holdings in LivaNova by 64.7% in the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock worth $29,824,000 after acquiring an additional 213,749 shares during the last quarter. Finally, Point72 DIFC Ltd raised its stake in LivaNova by 75,799.6% in the 3rd quarter. Point72 DIFC Ltd now owns 181,400 shares of the company’s stock valued at $9,531,000 after acquiring an additional 181,161 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.